A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer

This study is testing a new drug combination — BL-B01D1 (an antibody-drug conjugate that targets cancer cells) plus a TKI (targeted therapy pill) with or without pembrolizumab (an immunotherapy drug) — for people with locally advanced or metastatic kidney cancer (renal cell carcinoma). The goal is to see how effective and safe this combination is. **You may be eligible if...** - You are between 18 and 75 years old - You have been confirmed by biopsy to have advanced or metastatic kidney cancer (renal cell carcinoma) - You are in good general health (ECOG score 0 or 1) with a life expectancy of at least 3 months - You have at least one measurable tumor on imaging - Your organs are functioning adequately and prior cancer treatment side effects have resolved **You may NOT be eligible if...** - You have active brain metastases - You have another active cancer within the past 5 years - You have had a recent stroke, heart attack, or serious blood clot within 6 months - You have active hepatitis B, hepatitis C, HIV, or tuberculosis - You have autoimmune disease or are on immunosuppressive drugs - You have uncontrolled diabetes or severe lung disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.